CAB LA proves to be highly effective for prevention of HIV acquisition in cisgender men and transgender women

The HIV Prevention Trials Network (HPTN) announced today results from HPTN 083, a global randomized, controlled, double-blind study that compared the safety and efficacy of long-acting injectable cabotegravir (CAB LA) to daily oral tenofovir/emtricitabine (TDF/FTC) (Truvada) for pre-exposure prophylaxis (PrEP). The study showed that CAB LA lowered HIV incidence among cisgender men and transgender women who have sex with men. 

Press Release     Press Coverage     Press Briefing     

HPTN 083 FAQ     HPTN 083 Preliminary Study Results Webinar